Kornimate/medical-research-clean huggingface dataset:
evaluation of the functionality of an extract rich in phytosterols and phytostanols on parameters related to the lipid profile of individuals with hypercholesterolemia, mainly in the levels of total cholesterol, ldl cholesterol and oxidized ldl

Conditions: Cholesterol Lowering; LDL Level

Summary: the aim of this clinical trial is to evaluate the functionality of an extract rich in phytosterols and phytostanols on parameters related to the lipid profile of individuals with hypercholesterolemia, mainly on total cholesterol and ldl cholesterol levels

a total of 45 participants with hypercholesterolemia (total cholesterol\>200 mg/dl) will be recruited. participants must not be taking any medication or nutritional supplement aimed at lowering cholesterol levels. social networks and advertisements at the universidad católica san antonio de murcia (ucam) and the centro de edafología y biología aplicada del segura (cebas) will be used to recruit the individuals. first, participants will attend to an informative session to learn in more detail about the objectives of the study and the procedures to be followed. in this session participants will sign the informed consent. they will be divided into two groups: * one group (n=23) that will take an extract rich in phytosterols and phytostanols (mainly β-sitosterol, β-sitostanol, campesterol and stigmasterol), resveratrol and hydroxytyrosol. the extract will be taken in capsule format. * a control group (n=22) that will take a placebo supplement. at the beginning of the study, anthropometric measurements of the participants will be taken. the participants' blood pressure will also be measured. an interview-questionnaire will be conducted to learn about and evaluate participants´s diet, physical activity and sleep quality. a blood sample will also be taken from the participants for biochemical analysis (total cholesterol, hdl, ldl, oxidized ldl, triglycerides and transaminases). from this day on, all participants will take two capsules daily of the phytosterol-rich extract or the placebo capsule, as appropriate, for 56 days. capsules will be taken at night after dinner. sampling and biochemical analysis will be repeated on days 28 and 56.

Eligibility criteria:
inclusion criteria: total cholesterol\>=200 mg/dl - exclusion criteria: total cholesterol\<200 mg/dl -

Keywords: cholesterol ldl hdl oxidized ldl triglycerides phytosterols bioactive compounds resveratrol hydroxytosol
resolute onyx post-approval study

Conditions: Coronary Artery Disease

Summary: to observe the continued performance of the medtronic resolute onyx™ zotarolimus-eluting coronary stent system in a real-world more-comer population.


Eligibility criteria:
key inclusion criteria * symptomatic coronary artery disease including subjects with chronic stable angina, silent ischemia, and acute coronary syndromes including non-st elevation and st-elevation myocardial infarction * subject is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's instructions for use, and the declaration of helsinki key exclusion criteria * unprotected left main disease * subjects with planned pci of three vessel disease
longitudinal study of a bionic eye

Conditions: Retinitis Pigmentosa; Choroideremia

Summary: this is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.

to observe and assess visual, orientation and mobility behavior with primary and adjunct vision processing (avp) methods that may enhance the performance with the suprachoroidal retinal prosthesis (scrp). to investigate the effectiveness of primary and avp methods in the laboratory and real-world environments with the scrp. assess structural and functional scrp stability with objective and subjective assessments. record participant experiences and feedback with the scrp.

Eligibility criteria:
inclusion criteria: * willing to provide signed informed consent; * implanted with a suprachoroidal retinal prosthesis; * be available for the study visits; * willing to comply with study assessments; * in good general health and mobile. exclusion criteria: * medical condition that prohibits mobility; * anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
impact of canine mediation practice in psychomotor therapy on improving the quality of life in adult epileptic patients.

Conditions: Epilepsy

Summary: in addition to the search for new pharmaceutical or surgical solutions that could improve the therapeutic management of epileptic individuals, it is interesting to ask whether other complementary approaches, such as canine mediation in psychomotor therapy, could enhance the quality of life in this population. however, there is currently no evidence indicating that exposure to animals through mediation sessions would be beneficial for epileptic individuals, particularly regarding their quality of life, anxiety, emotional management, or cognition (such as social cognition). in the absence of current data in this population, it seems pertinent to study the impact of this practice on people with epilepsy. furthermore, beyond quality of life, it would be valuable to examine whether it also influences anxiety or the frequency of seizures in individuals with epilepsy (a phenomenon reported for epileptic individuals living with a pet dog or a service dog). canine mediation could help better manage and regulate the emotions of epileptic individuals, as well as improve their self-esteem.


Eligibility criteria:
inclusion criteria: * person aged ≥ 18 years * presenting pharmacoresistant epilepsy according to the criteria of the international league against epilepsy * requiring psychomotor therapy sessions for one of the following indications: difficult emotional and relational management and/or global motor difficulties and/or body schema organization disorder and/or temporo-spatial disorder * explicit consent or no opposition to participation in the study by the patient and/or their legal representative or guardian * image rights consented by the patient and their legal representative or guardian, if applicable * hospitalization or residence at the teppe institute or at the fam (foyer d'accueil médicalisé) des 4 jardins planned for at least 3 months * affiliated with or a beneficiary of a social security scheme exclusion criteria: * fear or phobia of dogs * epileptic person benefiting from a legal protection measure other than guardianship or curatorship * person with insufficient cognitive abilities to respond to the questionnaires * pregnant or breastfeeding woman
inventory of inappropriate prescriptions of proton pump inhibitors (ppis) in people over 75 years of age

Conditions: Peptic Ulcer Disease

Summary: this study would have as a starting point the results of a request carried out by the medical service grand est of the health insurance aiming to evaluate the number of boxes of ppi reimbursed in town pharmacy, in patients over 75 years old in the grand est of france from 01/01/2018 to 31/12/2018. it aims to highlight and quantify a possible inappropriate use of ppis in private practice.


Eligibility criteria:
inclusion criteria: * patient over 75 years of age * patient with a ppi in the initial prescription * patient seen at least once between 01/01/2018 and 31/11/2019 in the general practice * patient who has not expressed his opposition, after information, to the reuse of his data for the purpose of this research. exclusion criteria: * patient having expressed his opposition to participate in the study * impossibility to give the patient informed information (difficulties in understanding the subject, ...) * patient under legal protection * patient under guardianship or curatorship * patient who is no longer followed up in the office following an entry into an institution (ehpad)

Keywords: peptic ulcer disease proton pump inhibitors ppi
bitherapy with the combination of raltegravir and darunavir (birdi)

Conditions: Comorbidities; HIV/AIDS

Summary: retrospective cohort of virologically suppressed hiv-infected patients who received the combination of raltegravir plus darunavir boosted with cobicistat or ritonavir, as dual therapy, because or toxicity or intolerance to nucleoside analogues

this is a retrospective cohort study including those hiv-infected patients who received the combination of raltegravir plus darunavir boosted with cobicistat or ritonavir as dual therapy, due to the existence of toxicity or intolerance to nucleoside analogues, to evaluate: * efficacy, measured as percentage of patients free of virological failure after 48 and 96 weeks (itt-e, snapchot analysis) and improvement in cd4+ count * tolerance (rate of discontinuation and cause, and frequency of adverse events) * evolution of different comorbidities (renal, bone, cardiovascular events) patients will included if they have received at least 1 dose of the dual therapy

Eligibility criteria:
inclusion criteria: * hiv infection * older than 18 years * to have received the combination of raltegravir plus boosted darunavir in patients with virological suppression (more than 6 months) after toxicity or intolerance to nucleoside analogues exclusion criteria: * virological failure in the last 6 months previous to dual therapy * presence or suspicion of resistance to darunavir (major mutations according to meyer et al) or to raltegravir (major mutations according to ias list) * active hepatitis b

Keywords: hiv dual therapy comorbidities nucleoside analogues sparing-regimens
effect of adding dexamethasone to intrathecal bupivacaine on blood sugar of patients undergoing diabetic foot surgeries

Conditions: Diabetic Foot

Summary: effect of intrathecal dexamethasone on blood sugar of dietetic patients


Eligibility criteria:
inclusion criteria: * control diabetic patients will undergo foot surgeries. exclusion criteria: * the exclusion criteria included patient refusal, patients with major cardiac, respiratory, renal, hepatic disorders or uncontrolled diabetes mellitus, history of chronic use of analgesic medication or hypersensitivity to drugs under investigation, any contraindication to regional anesthesia, namely; patients with coagulopathy infection at puncture site, backache, spine deformity or prior surgery, neuromuscular disorders or psychic disturbances
diazoxide in the management of hypoglycemic neonates

Conditions: Infant, Newborn, Diseases; Pregnancy in Diabetics; Infant, Diabetic Mother; Hypoglycemia; Infant, Large for Gestational Age

Summary: diazoxide is an oral hyperglycemic medication. diazoxide has been proven effective for treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic hypoglycemia. the mechanism of action results in decreased insulin secretion. one of the causes of hypoglycemia in infants of diabetic mothers occurs due to a transient hyperinsulinemic state postnatally. the investigators have clinical experience and success using diazoxide in their unit for patients with hypoglycemia not adequately managed with intravenous (iv) dextrose and enteral supplementation. in this randomized controlled study the investigators expect that by using diazoxide as the initial treatment for infants of diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/l), the investigators will be able to decrease the number of infants requiring an intravenous by at least thirty percent.


Eligibility criteria:
inclusion criteria: * infants of diabetic mothers (idms) or infants weighing \>90% * hypoglycemia: two consecutive blood glucose measurements \ 1.9mmol/l in the first twelve hours of life * \> 36 weeks gestational age exclusion criteria: * infants with symptomatic hypoglycemia (regardless of value * infants who meet criteria for intravenous dextrose according to the canadian pediatric society (cps) position statement * infants with contraindications for enteral feeds and/or medications

Keywords: infants of diabetic mothers hypoglycemia diazoxide large for gestation infants
entyvio in bio-naive patients with moderate/severe crohn's disease (cd) in daily practice

Conditions: Crohn Disease

Summary: the purpose of this study is to describe physician-reported clinical effectiveness outcomes, as determined by harvey-bradshaw index (hbi) assessment, in biologic-naive participants with cd over 12 months following treatment initiation with vedolizumab.

this is a non-interventional, single-cohort, prospective study of participants with moderate to severe cd. the study will review medical charts with prospective patient-reported outcome measures to provide real-world data to describe clinical outcomes and participant-reported symptom experience over 12 months following vedolizumab treatment initiation. the study will enroll approximately 140 participants. all participants will be enrolled in one observational group: • vedolizumab this multicenter trial will be conducted in canada. the overall duration of study will be approximately 24 months, including participant's enrolment period of 12 months and follow-up data collection period of 12 months.

Eligibility criteria:
inclusion criteria: 1. is enrolled in takeda's participant support program prior to receiving vedolizumab. 2. has a diagnosis of moderately-to-severely active cd, as documented in the medical records. 3. scheduled for initial vedolizumab treatment per usual care recommendation. 4. was biologic-naive at time of initiating vedolizumab treatment. exclusion criteria: 1. was prescribed vedolizumab as part of a clinical study. 2. has isolated and active perianal disease in the absence of luminal cd.

Keywords: drug therapy
atv/ritonavir nevirapine interaction (uspac)

Conditions: HIV Infections

Summary: open-label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in hiv-infected individuals.


Eligibility criteria:
inclusion criteria: * signed informed consent form * for cohort 1, hiv-infected subjects receiving nevirapine 200 mg twice-daily and 2 to 3 nrtis for at least 6 weeks * for cohort 2, hiv-infected subjects receiving atazanavir 300 mg and ritonavir 100 mg once-daily and 2 to 3 nrtis for at least 6 weeks * have had 2 measurements of plasma hiv rna of \<400 copies/ml. the first test being 6 to 16 weeks prior and the second being within 3 weeks prior to day 1 * have cd4 cell count \>=200 cells/mm3 * body mass index of 18 to 35 kg/m2. * men and women, ages 18 to 55. exclusion criteria: * women who are pregnant or breastfeeding * presence of a newly diagnosed hiv-related opportunistic infection or cd4 cell count \<200 cell/mm3 within the previous 6 months. * any significant acute or chronic medical illness, unless stable or controlled by a non-prohibited medication. * history of virologic failure on an antiretroviral regimen.
group interpersonal psychotherapy for treatment of major depressive disorder following perinatal loss

Conditions: Major Depressive Disorder; Miscarriage; Stillbirth; Neonatal Death

Summary: the purpose of this study is to conduct a randomized pilot trial in a sample of 60 women who meet criteria for major depressive disorder (mdd) 1-18 months after a perinatal loss to demonstrate the feasibility of the proposed recruitment methods and research design, of the therapist training methods, and of delivering the adapted interpersonal psychotherapy group treatment. the investigators would like to examine preliminary evidence for the following hypotheses: * perinatal-loss specific ipt-g will be more acceptable to women who experience mdd following perinatal loss than will coping with depression (cwd). * perinatal-loss specific ipt-g will result in reduced time to remission from mdd and reduced depressive symptoms relative to cwd. * perinatal-loss specific ipt-g will result in increased social support and social functioning, reduced couple distress, and reduced grief relative to cwd.


Eligibility criteria:
inclusion criteria: * current major depressive episode. * experience perinatal loss 1-18 months prior to intake (including early and late fetal death and the death of a live born neonate within the first 28 days). exclusion criteria: * untreated thyroid difficulties (tsh levels out of the normal range). * anemia (hemoglobin or hematocrit out of the normal range). * onset of current major depressive episode prior to news of difficulties with the pregnancy or health risk to the infant (women with prior episodes will be included). * current or past diagnosis of bipolar i disorder, schizophrenia or other psychotic disorder. * primary diagnosis of substance dependence or eating disorder. * acute suicidal or homicidal risk. * non-stable course of antidepressant medication or psychotherapy (i.e., beginning or changing dose of either within the previous 8 weeks). * any ipt or cognitive-behavioral treatment in the previous 8 weeks.

Keywords: major depressive disorder (mdd) miscarriage stillbirth neonatal death interpersonal psychotherapy group therapy coping with depression (cwd)
chronic multimorbidity patterns in relation to covid-19 severe infection

Conditions: Covid-19; Chronic Disease

Summary: the aim of the study was to analyze the patterns of chronic multimorbidity of a cohort of covid-19 patients, and to assess the relation between the patterns and the development of severe infection or mortality.

this is a big data study that aims to establish the multimorbidity (mm) clusters of a cohort of covid-19 patients, and assess their potential relation with severe infection or mortality. databases of demographic information and complete medical records from the cohort will be provided by the agency for health quality and assessment of catalonia (aquas). data will be collected and integrated in a complete database in order to define the study variables: multimorbidity patterns, covid-19 severe infection and covid-19 associated mortality. the population will be stratified by sex and age (21-45, 46-65, 66-80 and 81-95 years). diagnoses from primary care and hospitals will be filtered and classified using the chronic condition indicator v.2021 and the clinical classification software v.2021 \[1\], in order to identify the chronic conditions (cc) of the patients. cc with prevalence \>2% in each age-sex strata will be subjected to a fuzzy c-means clustering analysis. the final number of clusters in each age-sex group will be determined under the clinical criteria of the research group members. percentages of patients that suffered severe covid-19 infection or death in each cluster will be calculated. bivariate statistical analysis comparing the demographic data and the cluster distribution with severe infection and mortality will be performed.

Eligibility criteria:
inclusion criteria: * positive results of covid-19 laboratory tests * covid-19 related clinical profile verified by healthcare professionals exclusion criteria: * male \>90 years * females \>95 years

Keywords: multimorbidity cluster analysis covid-19
mobile application-assisted pressure injury management

Conditions: Pressure Injury; Nursing Caries; Application Site Wound

Summary: pressure injuries develop due to decreased movement, especially in bedridden individuals receiving home care. in turkey, the management of pressure injuries is carried out by nurses in acute and long-term care settings, and mostly by caregivers for individuals receiving home care. studies have shown that individuals providing home care have a significant need for training. today, digital health technologies are used to facilitate access to healthcare professionals and provide workload and cost efficiency. telehealth services in these technologies can be provided via telephone or mobile applications. in this context, the aim of the study is to examine the effect of nursing services provided via mobile applications on the management of pressure injuries in individuals receiving home care. the study was designed as a randomized controlled experimental type. in the power analysis conducted to calculate the sample size, the sample size was determined as 56, and considering that there may be data losses, 60 people will be included in the study. the "structured information form, pressure injury information form for caregivers, pressure injury skill checklist for caregivers, and pressure injury follow-up form" will be used as data collection tools in the study. in this study, it is thought that the nurse's remote monitoring of individuals receiving home care with a mobile application in the management of pressure injuries will contribute to patient safety and care costs.


Eligibility criteria:
inclusion criteria: * individuals receiving home care and caregivers * individuals over the age of 18 * individuals with a caregiver who can use the mobile application (the mobile application will be introduced to the caregivers in the first meeting and consent will be obtained from the individual to use it) * individuals with a smartphone * individuals who can use a smartphone * individuals who fill in the data completely * individuals with a pressure injury exclusion criteria: * individuals who cannot use mobile applications * individuals who cannot use smartphones * individuals who want to leave the study * individuals who have incomplete data collected in the study for various reasons * individuals with chronic diseases (diabetes and hypertension)